Charles River Laboratories reported third-quarter results highlighted by revenue of $1.03 billion, a 4% increase from the prior-year period. The company has experienced pressure from cautious client spending patterns. This has created headwinds for the research models and services segment as biopharma customers have reprioritized pipelines and are conserving cash amid macroeconomic challenges.
Charles River’s reputation for quality and scientific expertise supports its leading position in the research model and preclinical trial markets.
Charles River does not have a long-term advantage in drug discovery, as we believe that will remain the core competency of biotechnology and pharmaceutical companies.
|
Metric
|
CRL
|
ICLR
|
LH
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.31 | 18.44 | 14.66 |
Price/Book Value | 3.17 | 2.50 | 2.34 |
Price/Sales | 2.50 | 2.81 | 1.50 |
Price/Cash Flow | 13.46 | 19.48 | 10.19 |
|
Metric
|
CRL
|
ICLR
|
LH
|
|---|---|---|---|
Quick Ratio | 0.96 | 1.14 | 0.96 |
Current Ratio | 1.45 | 1.19 | 1.36 |
Interest Coverage | 5.45 | 2.81 | 6.35 |
|
Metric
|
CRL
|
ICLR
|
LH
|
|---|---|---|---|
Return on Assets (Normalized) | 7.55% | 4.01% | 6.72% |
Return on Equity (Normalized) | 18.82% | 7.97% | 13.51% |
Return on Invested Capital (Normalized) | 10.91% | 7.30% | 9.13% |
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Clp | $189.2 Bil | |
DHR
| Danaher Corp | Crgvmq | $160.7 Bil | |
IDXX
| IDEXX Laboratories Inc | Qrtnyn | $44.1 Bil | |
IQV
| IQVIA Holdings Inc | Nfgtyn | $39.3 Bil | |
A
| Agilent Technologies Inc | Nxv | $37.2 Bil | |
MTD
| Mettler-Toledo International Inc | Vrfvdc | $23.6 Bil | |
ICLR
| Icon PLC | Rhsdqp | $22.4 Bil | |
LH
| Laboratory Corp of America Holdings | Hfjlzm | $18.4 Bil | |
ILMN
| Illumina Inc | Fwzlnjx | $17.9 Bil | |
WAT
| Waters Corp | Fft | $17.3 Bil |
:quality(80)/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)